Pfizer launches ophthalmics products group

Published: 25-Nov-2003

Pfizer has launched a new business group, Pfizer Ophthalmics, to bring together its own products with those of Pharmacia Corporation, which it acquired in April.


Pfizer has launched a new business group, Pfizer Ophthalmics, to bring together its own products with those of Pharmacia Corporation, which it acquired in April.

The Pfizer Ophthalmics product line includes Xalatan (latanoprost ophthalmic solution), a once daily treatment for the reduction of intraocular pres-sure in patients with open angle glaucoma or ocular hypertension. Also included is Zithromax -- an antibiotic that is highly effective against trachoma, the world's leading cause of preventable blindness. Trachoma is endemic in 48 countries, with an estimated 146 million infected.

The new business group is also studying the use of Macugen (pegaptanib sodium), a Phase III clinical trial drug which is being developed in partnership with New York-based biopharmaceutical company Eyetech Pharmaceuticals.

'Pfizer is making a significant commitment to dis-cover, develop and provide breakthrough treatments in ophthalmology,' said Pat Kelly, president, Pfizer US Pharmaceuticals.

You may also like